Investor Summary
Fund Strategy
FUND PERFORMANCE AS OF 31st December 2025
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 11.5% | - | 10.5% |
| 2025 | 2024 |
|---|---|
| 10.5% | 19.6% |
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 11.5% | - | 10.5% |
| 2025 | 2024 |
|---|---|
| 10.5% | 19.6% |
The Mairs & Power Growth Fund returned 10.54% in 2025, underperforming the S&P 500's 17.88% return due to stock selection challenges and avoiding overvalued AI-related companies. Key detractors included Fiserv and UnitedHealth Group, which experienced execution missteps and leadership uncertainty, while JPMorgan Chase and Roche were notable contributors. The fund added Zoetis and Intuitive Surgical during the fourth quarter, both companies positioned to leverage AI for long-term competitive advantages in animal health and robotic surgery respectively. The managers believe the market is entering a transition period for AI, with signals pointing to a higher risk phase given excessive capital flows and unusual financing structures. Despite underperformance from valuation discipline, the fund maintains its approach of investing in companies with durable competitive advantages at reasonable valuations. Looking ahead, they expect lower interest rates and improved small business conditions to support economic growth, while remaining cautious about AI-related structural unemployment risks and maintaining diversification across sectors and investment themes.
Focus on companies with durable competitive advantages that can harness AI and technological advancement for long-term growth, while maintaining valuation discipline in an environment of elevated AI-related valuations and market concentration.
The fund believes we are entering a transition period for AI, with the initial excitement of the building-out phase often short lived. They remain focused on identifying businesses that will harness technological advancement over the long-term, not just during the initial build-out, believing this approach will increase competitive advantages and growth rates while being prudent for compounding and protecting wealth.
| Date | Letter | Tickers | Keywords | Pitches | Quick Takes |
|---|---|---|---|---|---|
| Jan 18 2026 | 2025 Q4 | FI, HRL, ISRG, JPM, MSFT, MSI, NVDA, NVT, RHHBY, TECH, UNH, ZTS | AI, growth, healthcare, large cap, technology, valuation | - | AI and increasing market concentration took center stage in 2025, driving market narrative with valuations pushing higher and corporate spending accelerating. The fund believes we… |
| Oct 24 2025 | 2025 Q3 | CGNX, JPM, PANW, UNH | AI, Cloud, cybersecurity, Machine Vision, semiconductors | - | The portfolio participates in AIs secular adoption while trimming exuberant names; additions in machine vision and cybersecurity target durable, compounding growth. Managers stress that leadership… |
| Jul 18 2025 | 2025 Q2 | IDA, JPM, MEDP, META, MSFT, UNH | Competitive Advantage, earnings, innovation, Reinvestment, secular growth | - | The letter highlights durable earnings growth driven by innovation, market leadership, and reinvestment discipline. Management favors companies with strong competitive advantages and long growth runways.… |
| May 1 2025 | 2025 Q1 | TSM | - | - | - |
| Dec 31 2024 | 2024 Q4 | CLFD, NVDA | - | - | - |
| Sep 30 2024 | 2024 Q3 | KHC, TTC, UNH | - | - | - |
| Jul 23 2024 | 2024 Q2 | NVDA, NVT, QCOM | - | - | - |
| Apr 15 2024 | 2024 Q1 | CASY, NVDA, RHHBY, ULTA, VZ | - | - | - |
| Jan 28 2024 | 2023 Q4 | BBY, GOOG, MSFT, PIPR | - | - | - |
| Sep 30 2023 | 2023 Q3 | TTC, VZ | - | - | - |
| Jun 30 2023 | 2023 Q2 | AMZN, MSFT, NVDA | - | - | - |
| Apr 19 2023 | 2023 Q1 | - | - | - | - |
| Feb 2 2023 | 2022 Q4 | ECL, GOOGL, TECHNE, TTC, UNH | - | - | - |
| QUARTER | THEMES | TAGS |
|---|---|---|
| 2025 Q4 |
AIAI has been integrated into RGA's research process through tools like NotebookLM, Gems in Gemini, and Claude Code. The firm views AI as a force multiplier for human judgment rather than a replacement, emphasizing the Kasparov Law principle. They believe the market narrative around AI displacement is swinging to unhelpful extremes, creating investment opportunities. |
Machine Learning Automation Software Productivity Innovation |
HealthcareHealthcare was the strongest relative contributor in the quarter with holdings increasing nearly +16% compared to benchmark returns of roughly +12%. Exact Sciences was acquired for a significant premium by Abbott Laboratories resulting in an +86% return, while other strong performers included Tarsus Pharmaceuticals, Glaukos following approval of a new product, Penumbra, and Repligen driven by strong earnings results. |
M&A Product Approval Earnings Biotech | |
ValuationAI-related companies continue to command premium valuations while other sectors remain reasonably priced. This valuation divide continues to guide investment activity, with the fund remaining wary of companies trading at exceedingly high valuations that imply exceptional multi-year earnings growth. |
Premium Divide Discipline Stretched Reasonable | |
| 2025 Q3 |
AIAI has been integrated into RGA's research process through tools like NotebookLM, Gems in Gemini, and Claude Code. The firm views AI as a force multiplier for human judgment rather than a replacement, emphasizing the Kasparov Law principle. They believe the market narrative around AI displacement is swinging to unhelpful extremes, creating investment opportunities. |
Machine Learning Automation Software Productivity Innovation |
AutomationFactory automation represents long-term structural growth opportunity. Keyence leads in sensors and machine-vision systems with 80% margins supported by direct sales model. Structural trends include rising automation, reshoring, and growing complexity in electric vehicle manufacturing providing long runway for growth. |
Factory Automation Industrial Sensors Machine Vision Robotics Industrial IoT | |
| 2025 Q2 |
Growth |
| Date | Pitch Type | Author | Ticker | Company | Industry | Sub Industry | Bull / Bear | Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| No Elevator Pitches found | ||||||||||
| TICKER | COMMENTARY |
|---|---|
| FI | Notable detractors from performance came from Fiserv (-43bps absolute and -39bps relative) |
| HRL | Other increasers included Hormel Foods |
| ISRG | ISRG shares appreciated in the fourth quarter after the company delivered strong Q3 results highlighting continued procedure growth and accelerating system placements. Procedure volumes rose in the mid-teens globally, with notable strength in general surgery and urology, while recurring instrument and accessory revenue grew faster than expectations. Management also reported that the early rollout of its next-generation robotic platform was tracking ahead of schedule, with utilization metrics trending positively across beta sites. |
| JPM | JPMorgan (JPM) has identified 42 AI-related stocks in the S&P 500, which today represent 45% of the index's market cap. They estimate that these stocks have accounted for 78% of S&P 500 returns, 66% of earnings growth, and 71% of capital spending growth since ChatGPT launched in November 2022. As it relates to the impact on the U.S. economy, JPM estimates tech sector capital spending contributed 40%-45% of U.S. GDP growth through the first 9 months of the year, up from less than 5% during the same period in 2023. |
| MSFT | MSFT was a detractor in 4Q25 following its fiscal first-quarter 2026 earnings report released on October 29. While results were better than expected operationally, investor reaction was driven by guidance and capital expenditure intensity rather than headline performance. Revenue grew 17% year-over-year, exceeding consensus expectations, and Azure revenue increased 39% year-over-year, also ahead of estimates. However, management guided to a sequential deceleration in Azure growth in fiscal Q2, signaling some moderation after a period of exceptional demand. |
| MSI | For Motorola Solutions (MSI), underlying results remain quite positive, but a recent acquisition is expected to dilute earnings at a time when tariff headwinds are expected to create near-term margin pressure. |
| NVDA | AI bellwether NVIDIA's very strong set of earnings in late November helped the AI theme re-assert its dominance when investors breathed a sigh of relief following the results. |
| NVT | nVent had a positive 2025 due to surging data center demand related to liquid cooling of servers and a key acquisition helping to improve revenue. |
| RHHBY | Roche (RHHBY) was another positive performer in 2025, driven by a robust pipeline of new and innovative drugs making it to market and favorable regulatory approvals. |
| TECH | Bio-Techne is a leader in the life sciences research market with a broad portfolio of products that are used to enable discoveries of new drugs, therapeutics, and diagnostics. These products include over 6,000 proteins, 400,000 antibody types, and 2,400 diagnostic assays. Around 80% of the business is recurring revenues. We are encouraged by the new CEO's strategy to leverage the core business and expand the company's leadership position in protein research. Consternation surrounding the health of customer research spending gave us the opportunity to buy the stock at a discount to our estimate of intrinsic value. |
| UNH | We also added back a full position in UnitedHealth |
| ZTS | ZTS: $6B authorized August 2024; $1.5B used as of September 2025 |
| Ticker | Put/Call | Amount Bought | Shares Bought | % Change | Weight % |
|---|---|---|---|---|---|
| No Recent Buys Data | |||||
| Ticker | Put/Call | Amount Sold | Shares Sold | % Change | Weight % | Status |
|---|---|---|---|---|---|---|
| No Recent Sells Data | ||||||
| Industry | Prev Quarter % | Current Quarter % | Change |
|---|---|---|---|
| No industry data available | |||